Bliss GVS Pharma Complete Financial Statements
BLISSGVS • Review detailed financials to uncover trends, confirm thesis & journal trades
11 Years of Data
2025 - 2015
Complete Financial Data Export
Export complete financial statements for Bliss GVS Pharma (BLISSGVS).
Downloads include all available records across all periods.
Profitability Ratios
Net Profit Margin
11.46%
2025 data
EBITDA Margin
20.55%
2025 data
Operating Margin
18.00%
2025 data
Return on Assets
2.23%
2025 data
Return on Equity
2.66%
2025 data
Balance Sheet Ratios
Current Ratio
22.35
2025 data
Equity Ratio
83.94%
2025 data
Asset Turnover
0.19
2025 data
Year-over-Year Growth Analysis
Comparing Sept 2024 vs Sept 2025
Revenue Growth
+13.5%
Year-over-Year
Net Profit Growth
+11.5%
Year-over-Year
EBITDA Growth
+10.6%
Year-over-Year
Expense Growth
+14.2%
Year-over-Year
Assets Growth
+7.3%
Year-over-Year
Equity Growth
+8.9%
Year-over-Year
Operating Cash Flow Growth
+2.9%
Year-over-Year
Investing Cash Flow Growth
+9.6%
Year-over-Year
Financing Cash Flow Growth
-42.9%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Mar 2016 | Jun 2016 | Dec 2016 | Sept 2015 | Jun 2015 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 253 | 210 | 243 | 237 | 223 | 204 | 188 | 226 | 225 | 188 | 165 | 206 | 175 | 179 | 196 | 211 | 201 | 138 | 176 | 222 | 154 | 139 | 137 | 168 | 223 | 247 | 214 | 153 | 253 | 173 | 219 | 217 | 239 | 241 | 226 | 198 | 162 | 148 | 146 | 235 | 184 | 100 | 138 |
| Expenses | 201 | 177 | 166 | 186 | 176 | 199 | 149 | 181 | 158 | 179 | 135 | 157 | 148 | 147 | 150 | 158 | 167 | 115 | 134 | 256 | 120 | 117 | 110 | 126 | 185 | 212 | 163 | 115 | 187 | 164 | 165 | 177 | 179 | 182 | 161 | 148 | 126 | 95 | 101 | 187 | 132 | 60 | 104 |
| EBITDA | 52 | 33 | 77 | 51 | 47 | 5 | 39 | 45 | 67 | 9 | 29 | 49 | 27 | 32 | 46 | 53 | 35 | 23 | 42 | -33 | 35 | 21 | 27 | 42 | 38 | 35 | 51 | 39 | 66 | 9 | 55 | 40 | 61 | 60 | 65 | 50 | 36 | 52 | 46 | 48 | 51 | 40 | 34 |
| Operating Profit Margin % | 18.00% | 11.00% | 20.00% | 15.00% | 19.00% | 0.00% | 19.00% | 14.00% | 26.00% | 3.00% | 15.00% | 22.00% | 14.00% | 12.00% | 21.00% | 23.00% | 15.00% | 13.00% | 21.00% | -18.00% | 21.00% | 2.00% | 15.00% | 23.00% | 12.00% | 13.00% | 23.00% | 22.00% | 18.00% | 2.00% | 20.00% | 20.00% | 20.00% | 27.00% | 28.00% | 25.00% | 21.00% | 34.00% | 27.00% | 18.00% | 25.00% | 36.00% | 21.00% |
| Depreciation | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 8 | 6 | 5 | 6 | 7 | 5 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 4 | 2 | 3 | 3 | 2 | 5 | 2 | 2 | 5 | 1 | 5 | 7 | 4 | 2 | 4 | 11 | 6 | 3 | 3 |
| Interest | 3 | 2 | 6 | 2 | 4 | 2 | 2 | 1 | 2 | 5 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 5 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 6 | 8 | 7 | 5 | 4 | 7 | 4 | 4 | 5 | 5 | 2 |
| Profit Before Tax | 41 | 23 | 63 | 41 | 36 | -4 | 30 | 36 | 59 | -1 | 22 | 40 | 20 | 27 | 39 | 47 | 30 | 17 | 37 | -39 | 30 | 13 | 20 | 37 | 34 | 32 | 47 | 34 | 63 | -1 | 51 | 37 | 52 | 60 | 56 | 39 | 36 | 43 | 41 | 38 | 41 | 33 | 31 |
| Tax | 12 | 7 | 19 | 16 | 10 | 1 | 8 | 11 | 16 | -4 | 7 | 11 | 4 | 3 | 12 | 18 | 8 | 8 | 11 | 10 | 8 | 8 | 4 | 10 | 3 | 13 | 14 | 9 | 21 | 12 | 12 | 9 | 12 | 18 | 19 | 13 | 15 | 15 | 13 | 17 | 13 | 13 | 7 |
| Net Profit | 29 | 17 | 44 | 25 | 26 | -5 | 22 | 26 | 43 | 4 | 14 | 29 | 16 | 24 | 28 | 30 | 22 | 8 | 26 | -49 | 22 | 6 | 17 | 28 | 31 | 19 | 33 | 26 | 42 | -14 | 39 | 27 | 40 | 43 | 37 | 26 | 21 | 29 | 28 | 22 | 28 | 20 | 24 |
| Earnings Per Share (₹) | 2.58 | 1.47 | 4.08 | 2.20 | 2.31 | -0.88 | 1.97 | 2.27 | 4.06 | 0.34 | 1.41 | 2.64 | 1.33 | 1.90 | 2.48 | 2.68 | 2.05 | 0.61 | 2.35 | -4.83 | 1.99 | 0.85 | 1.57 | 2.48 | 3.00 | 1.76 | 3.28 | 2.30 | 4.02 | -1.39 | 3.72 | 2.50 | 4.93 | 3.21 | 2.05 | 1.74 | 2.46 | 1.71 | 2.67 | 2.02 | 2.23 | 1.89 | 2.15 |
Related Pages for Bliss GVS Pharma
Additional stock information and data for BLISSGVS
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 1,301 | 1,212 | 1,157 | 1,109 | 1,077 | 1,027 | 905 | 860 | 1,023 | 762 | 662 |
| Current Assets | 827 | 811 | 697 | 777 | 765 | 770 | 694 | 690 | 566 | 471 | 417 |
| Fixed Assets | 406 | 370 | 379 | 282 | 234 | 242 | 146 | 143 | 305 | 225 | 234 |
| Capital Work in Progress | 21 | 8 | 3 | 22 | 2 | 0 | 47 | 1 | 4 | 9 | 0 |
| Investments | 4 | 4 | 8 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 870 | 830 | 768 | 803 | 840 | 786 | 712 | 717 | 714 | 527 | 428 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 37 | 51 | 46 | 29 | 45 | 46 | 38 | 13 | 33 | 50 | 68 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 1,092 | 1,003 | 917 | 847 | 828 | 750 | 660 | 548 | 553 | 446 | 352 |
| Share Capital | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | 1,040 | 957 | 874 | 808 | 798 | 725 | 636 | 526 | 476 | 402 | 327 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 106 | 103 | 34 | 136 | 64 | 47 | 40 | 18 | 290 | 113 | 38 |
| Investing Activities | -75 | -83 | -6 | -103 | -45 | -40 | -79 | 48 | -249 | -50 | -30 |
| Financing Activities | -30 | -21 | -25 | -24 | -21 | -6 | 17 | -76 | -10 | -40 | -42 |
| Net Cash Flow | 0 | -1 | 3 | 9 | -2 | 0 | -22 | -11 | 30 | 23 | -34 |